Literature DB >> 26004569

Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.

Cristiano Matos1, Florence van Hunsel, João Joaquim.   

Abstract

BACKGROUND: New pharmacovigilance legislation allows consumers to report adverse drug reactions (ADRs) directly to competent authorities in all European Union countries. Consumer reporting is available in Portugal since July 2012. In 2013, the National Pharmacovigilance System (SNF) had received 3461 spontaneous ADR reports, of which only 1.4% (n = 50) were from consumers. Consumer reporting could be one opportunity to reduce underreporting. AIM: The aim of this study was to describe the attitudes and knowledge of the general public regarding spontaneous reporting and the reasons and opinions that can influence consumers' ADR underreporting.
METHODS: A descriptive-correlational study was performed looking for consumers' attitudes and knowledge regarding spontaneous reporting. A 6-month survey was conducted from June to November 2013 in general adult consumers from a community pharmacy in Coimbra, Portugal, who used prescribed medicines or over-the-counter (OTC) drugs. Attitudes and opinions were surveyed by personal interview in a closed-answer questionnaire using a Likert scale. Questionnaires from healthcare professionals or incomplete ones were not considered. Data were analyzed using descriptive statistics, chi-square (χ(2)) tests, and Spearman's correlation coefficients.
RESULTS: One thousand eighty-four questionnaires were collected (response rate of 81.1%) and 948 completed were selected for analysis. Of the respondents, 44.1% never heard about SNF. Younger people and those with a higher education were significantly more likely to be aware of SNF. Only one consumer had previously reported directly an ADR. Reporting ADRs indirectly through a healthcare professional (HCP) was preferred by 62.4%. The main reasons for consumers reporting spontaneous ADR would be the severity of reactions (81.1% agreed or strongly agreed) and worries about their situation (73.4% agreed or strongly agreed). Only weak and moderate correlations were found between studied statements..
CONCLUSIONS: Consumers are more likely to do spontaneous report about severe reactions or if they are worried about the symptoms. Tailored and proactive information on ADR reporting and educational interventions on consumers could increase the number of reports from consumers in Portugal.

Entities:  

Mesh:

Year:  2015        PMID: 26004569     DOI: 10.1007/s00228-015-1867-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Reasons for reporting adverse drug reactions--some thoughts based on an international review.

Authors:  C Biriell; I R Edwards
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-01       Impact factor: 2.890

2.  Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal.

Authors:  Maria Teresa Herdeiro; Inês Ribeiro-Vaz; Mónica Ferreira; Jorge Polónia; Amílcar Falcão; Adolfo Figueiras
Journal:  Drug Saf       Date:  2012-08-01       Impact factor: 5.606

3.  Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Determinants of under-reporting of adverse drug reactions: a systematic review.

Authors:  Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.

Authors:  Joana Marques; Inês Ribeiro-Vaz; Altamiro Costa Pereira; Jorge Polónia
Journal:  Int J Pharm Pract       Date:  2013-11-05

6.  Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden.

Authors:  Elisabet Ekman; M Bäckström
Journal:  Eur J Clin Pharmacol       Date:  2008-09-30       Impact factor: 2.953

7.  Attitudes to adverse drug reaction reporting.

Authors:  W H Inman
Journal:  Br J Clin Pharmacol       Date:  1996-05       Impact factor: 4.335

8.  The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study.

Authors:  Florence van Hunsel; Attje Talsma; Eugène van Puijenbroek; Lolkje de Jong-van den Berg; Kees van Grootheest
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-28       Impact factor: 2.890

9.  Adverse drug reaction reports of patients and healthcare professionals-differences in reported information.

Authors:  Leàn Rolfes; Florence van Hunsel; Sarah Wilkes; Kees van Grootheest; Eugène van Puijenbroek
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-07-31       Impact factor: 2.890

10.  Motives for reporting adverse drug reactions by patient-reporters in the Netherlands.

Authors:  Florence van Hunsel; Christine van der Welle; Anneke Passier; Eugène van Puijenbroek; Kees van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2010-07-24       Impact factor: 2.953

View more
  10 in total

1.  Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities' Views and Needs.

Authors:  Cristiano Matos; Linda Härmark; Florence van Hunsel
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

2.  Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana.

Authors:  George Tsey Sabblah; Delese Mimi Darko; Hudu Mogtari; Linda Härmark; Eugène van Puijenbroek
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

3.  Inappropriate Prescriptions in Older People-Translation and Adaptation to Portuguese of the STOPP/START Screening Tool.

Authors:  Luís Monteiro; Matilde Monteiro-Soares; Cristiano Matos; Inês Ribeiro-Vaz; Andreia Teixeira; Carlos Martins
Journal:  Int J Environ Res Public Health       Date:  2022-06-04       Impact factor: 4.614

4.  General Public Views, Attitudes, and Experiences toward Drug Safety in Dubai, United Arab Emirates: A Qualitative Approach.

Authors:  Doaa Alkhalidi; Shazia Qasim Jamshed; Ramadan Mohamed Elkalmi; Mirza Rafi Baig; Adeel Aslam; Mohamed Azmi Hassali
Journal:  Pharmacy (Basel)       Date:  2019-02-07

5.  Diabetes patient's pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation.

Authors:  Cristiano Matos; Florence van Hunsel; Rogério Tavares Ribeiro; Dulce Nascimento do Ó; João Filipe Raposo
Journal:  Ther Adv Drug Saf       Date:  2020-09-04

6.  Consumers' adverse drug event reporting via community pharmacists: three stakeholder perception.

Authors:  Tanattha Kitisopee; Jirunya Assanee; Bernard A Sorofman; Suntaree Watcharadmrongkun
Journal:  J Pharm Policy Pract       Date:  2022-03-14

7.  A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China.

Authors:  Ningsheng Wang; Yue Chen; Biqi Ren; Yufang Xiang; Nan Zhao; Xianyan Zhan; Bianling Feng
Journal:  BMC Health Serv Res       Date:  2022-03-08       Impact factor: 2.655

8.  Consumer opinions on adverse events associated with medicines and vaccines.

Authors:  Parisa Aslani; Kim Hamrosi; Vivien Tong; Timothy F Chen; Jane Cook; Romano Fois; Theresa McGarry; Carter Moore; Rodney Peters; Sarah Spagnardi; Karen Whitelock
Journal:  Patient Prefer Adherence       Date:  2018-07-31       Impact factor: 2.711

9.  Qualitative Study of General Public Views towards Adverse Drug Reactions in Lithuania.

Authors:  Agne Valinciute-Jankauskiene; Kubiliene Loreta
Journal:  Healthcare (Basel)       Date:  2021-03-09

10.  Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK.

Authors:  Sieta T de Vries; Petra Denig; Adriana Andrić; Marina Dimov Di Giusti; Alicia Ptaszynska-Neophytou; Linda Härmark; Peter G M Mol
Journal:  Drug Saf       Date:  2021-08-08       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.